Now Reading: Meiji Seika ties with SII to launch JE vaccine in India
-
01
Meiji Seika ties with SII to launch JE vaccine in India
Meiji Seika Pharma has partnered with Serum Institute of India to bring a Japanese Encephalitis vaccine to the country. The SII will seek regulatory approval next year and market the shot at…
Meiji Seika Pharma has partnered with Serum Institute of India to bring a Japanese Encephalitis vaccine to the country. The SII will seek regulatory approval next year and market the shot at the lowest possible cost, according to Meiji Seika's pharma COO Toshiaki Nagasato, who met commerce minister Piyush Goyal in Tokyo on Monday.
Meiji Seika also owns Indian subsidiary Medreich Pharma, acquired in 2014, and is looking to expand its generics capacity in India as well as exports to the UK, Canada and Africa. The company declined to disclose the investment amount. The WHO recognises three types of JE vaccines, Japan's technology combined with SII's low-cost manufacturing is intended to help protect Indian children.
Indian Opinion Analysis
Japanese encephalitis is a leading cause of viral encephalitis in Asia, with children bearing the heaviest burden. The WHO estimates about 68,000 clinical cases occur globally each year. India runs a routine immunisation programme that already includes a locally produced vaccine, but the Meiji-Seika Serum Institute partnership brings a different technology platform. The key hurdle, as the companies signal, is the regulatory approval process under India's Central Drugs Standard Control Organisation. That clearance and the final per-dose price the Serum Institute sets will determine how quickly the vaccine reaches the National Immunisation Schedule.
Source: timesofindia.indiatimes.com
This story was synthesised by AI from the source linked above.
